Tocilizumab versus anakinra in COVID-19: results from propensity score matching

BackgroundTocilizumab and anakinra are anti-interleukin drugs to treat severe coronavirus disease 2019 (COVID-19) refractory to corticosteroids. However, no studies compared the efficacy of tocilizumab versus anakinra to guide the choice of the therapy in clinical practice. We aimed to compare the o...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Robin Arcani, Florian Correard, Pierre Suchon, Gilles Kaplanski, Rodolphe Jean, Raphael Cauchois, Marine Leprince, Vincent Arcani, Julie Seguier, Benjamin De Sainte Marie, Baptiste Andre, Marie Koubi, Pascal Rossi, Stéphane Gayet, Nirvina Gobin, Victoria Garrido, Joris Weiland, Elisabeth Jouve, Anne-Laure Couderc, Patrick Villani, Aurélie Daumas
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2023-05-01
Serija:	Frontiers in Immunology
Teme:	anakinra tocilizumab anti-interleukin drugs COVID-19 mortality SARS-CoV-2
Online dostop:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1185716/full
Oznake:	Označite Brez oznak, prvi označite!